Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung

Executive Summary

New data for AMG 510 at ESMO show the drug is more active in lung than colorectal cancer, as was reported at ASCO, but Amgen's Greg Friberg notes that Phase I monotherapy and planned combination studies may shed more light on KRAS biology and efficacy in different tumor types.

You may also be interested in...

Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field

Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients. 

Amgen’s Lumakras Falls Short Of Mirati’s Adagrasib In Pancreatic Cancer

The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.

Lumakras A Big Focus For Amgen; More Data Coming Soon

Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts